Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Issue 11 (19th September 2021)

• Record Type: Journal Article
• Authors: Patel, Kishan K.; Parker, Terri; Di, Mengyang; Bar, Noffar; Huntington, Scott F.; Giri, Smith
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 11(2021)
• Page Start: 2777
• Page End: 2784
• Publication Date: 2021-09-19
• Subjects: Selinexor -- cost-effectiveness -- myeloma; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1933477
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The BOSTON trial showed that use of once-weekly selinexor, bortezomib, and dexamethasone (SVd) prolonged progression-free survival compared to twice-weekly bortezomib and dexamethasone (Vd) in patients with relapsed or refractory (R/R) multiple myeloma (MM). In this study, we constructed a Markov model to assess the cost-effectiveness of SVd versus Vd in R/R MM. We calculated the incremental cost-effectiveness ratio (ICER) of each treatment strategy from a US payer perspective, using a lifetime horizon and a willingness-to-pay threshold of $150, 000 per quality-adjusted life-year (QALY). Use of SVd was associated with an incremental cost of $170, 002 compared to Vd alone ($1, 015, 120 vs. $845, 118, respectively), an incremental effectiveness of 0.35 QALYs (3.43 vs. 3.08 QALYs, respectively), and an ICER of $487, 361/QALY. These data suggest that use of once-weekly SVd for R/R M/M is unlikely to be cost-effective compared to twice-weekly Vd.